Scleroderma, Systemic

12 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Narrower: Scleroderma, Diffuse 6

Treatments and conditions

Scleroderma, Systemic
Treatment and conditionWhere it standsTrials
AdMSC for scleroderma, systemicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for scleroderma, diffusePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
anti-CD19 CAR-T cells for scleroderma, systemicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AZD0120 for scleroderma, systemicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Belimumab for scleroderma, diffusePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
CAR-T cells targeting CD19 for scleroderma, systemicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide + FLUDARABINE + Prulacabtagene Leucel for scleroderma, systemicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
MTX-474 for scleroderma, diffusePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
QEL-005 for scleroderma, diffusePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rituximab + belimumab for scleroderma, systemicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Telitacicept for scleroderma, diffusePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tulisokibart for scleroderma, diffusePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.